

# Annamaria Vezzani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7455439/annamaria-vezzani-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255  
papers

24,044  
citations

81  
h-index

151  
g-index

267  
ext. papers

27,417  
ext. citations

6.4  
avg, IF

7.11  
L-index

#	Paper	IF	Citations
255	Lipid mediator n-3 docosapentaenoic acid-derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G-protein-coupled receptor.. <i>FASEB Journal</i> , <b>2022</b> , 36, e22203	0.9	3
254	A mathematical model of neuroimmune interactions in epileptogenesis for discovering treatment strategies. <i>IScience</i> , <b>2022</b> , 104343	6.1	
253	High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. <i>Epilepsia</i> , <b>2021</b> , 63, e1	6.4	1
252	Climate change and epilepsy: Insights from clinical and basic science studies. <i>Epilepsy and Behavior</i> , <b>2021</b> , 116, 107791	3.2	7
251	In-depth characterization of a mouse model of post-traumatic epilepsy for biomarker and drug discovery. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 76	7.3	8
250	Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. <i>Epilepsia Open</i> , <b>2021</b> , 6, 276-296	4	5
249	Microglia proliferation plays distinct roles in acquired epilepsy depending on disease stages. <i>Epilepsia</i> , <b>2021</b> , 62, 1931-1945	6.4	3
248	A team science approach to discover novel targets for infantile spasms (IS). <i>Epilepsia Open</i> , <b>2021</b> , 6, 49-61		1
247	The association between systemic autoimmune disorders and epilepsy and its clinical implications. <i>Brain</i> , <b>2021</b> , 144, 372-390	11.2	5
246	Chromosome 14 deletions, rings, and epilepsy genes: A riddle wrapped in a mystery inside an enigma. <i>Epilepsia</i> , <b>2021</b> , 62, 25-40	6.4	0
245	Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop. <i>Epilepsia Open</i> , <b>2021</b> , 6, 62-72	4	8
244	Emerging Molecular Mechanisms of Neuroinflammation in Seizure Disorders. <i>Agents and Actions Supplements</i> , <b>2021</b> , 21-43	0.2	1
243	Targeting Oxidative Stress with Antioxidant Duootherapy after Experimental Traumatic Brain Injury. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
242	A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies. <i>Neuropathology and Applied Neurobiology</i> , <b>2021</b> ,	5.2	2
241	Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study. <i>Neurology</i> , <b>2021</b> , 97, e1757-e1767	6.5	2
240	CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy. <i>Neurobiology of Disease</i> , <b>2021</b> , 158, 105468	7.5	5
239	The ENIGMA-Epilepsy working group: Mapping disease from large data sets. <i>Human Brain Mapping</i> , <b>2020</b> ,	5.9	18

238	Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. <i>Pharmacological Reviews</i> , <b>2020</b> , 72, 606-638	22.5	121
237	Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?. <i>Epilepsia</i> , <b>2020</b> , 61, 359-386	6.4	29
236	Brain Inflammation and Seizures: Evolving Concepts and New Findings in the Last 2 Decades. <i>Epilepsy Currents</i> , <b>2020</b> , 20, 40S-43S	1.3	11
235	White matter abnormalities across different epilepsy syndromes in adults: an ENIGMA-Epilepsy study. <i>Brain</i> , <b>2020</b> , 143, 2454-2473	11.2	32
234	Inflammation and reactive oxygen species as disease modifiers in epilepsy. <i>Neuropharmacology</i> , <b>2020</b> , 167, 107742	5.5	49
233	Inflammation and reactive oxygen species in status epilepticus: Biomarkers and implications for therapy. <i>Epilepsy and Behavior</i> , <b>2019</b> , 101, 106275	3.2	34
232	Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. <i>Brain</i> , <b>2019</b> , 142, e39	11.2	72
231	Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection-related epilepsy syndrome. <i>Epilepsia Open</i> , <b>2019</b> , 4, 344-350	4	49
230	Febrile Response and Seizures <b>2019</b> , 403-411		
229	TLR3 preconditioning induces anti-inflammatory and anti-ictogenic effects in mice mediated by the IRF3/IFN- $\beta$ axis. <i>Brain, Behavior, and Immunity</i> , <b>2019</b> , 81, 598-607	16.6	10
228	Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. <i>Nature Reviews Neurology</i> , <b>2019</b> , 15, 459-472	15	225
227	Changes of dimension of EEG/ECOG nonlinear dynamics predict epileptogenesis and therapy outcomes. <i>Neurobiology of Disease</i> , <b>2019</b> , 124, 373-378	7.5	6
226	Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence. <i>Brain Pathology</i> , <b>2019</b> , 29, 351-365	6	30
225	Intrinsic Inflammation Is a Potential Anti-Epileptogenic Target in the Organotypic Hippocampal Slice Model. <i>Neurotherapeutics</i> , <b>2018</b> , 15, 470-488	6.4	13
224	miR147b: A novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes. <i>Glia</i> , <b>2018</b> , 66, 1082-1097	9	23
223	Neuroinflammation Alters Integrative Properties of Rat Hippocampal Pyramidal Cells. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 7500-7511	6.2	27
222	Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. <i>Brain</i> , <b>2018</b> , 141, 391-408	11.2	187
221	Commonalities in epileptogenic processes from different acute brain insults: Do they translate?. <i>Epilepsia</i> , <b>2018</b> , 59, 37-66	6.4	123

220	Epilepsy. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 18024	51.1	269
219	High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy. <i>Brain, Behavior, and Immunity</i> , <b>2018</b> , 72, 14-21	16.6	60
218	Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 91-111	5.2	123
217	Ictogenic and Epileptogenic Mechanisms of Neuroinflammation: Insights From Animal Models <b>2018</b> , 23-31		
216	Pharmacological targeting of brain inflammation in epilepsy: Therapeutic perspectives from experimental and clinical studies. <i>Epilepsia Open</i> , <b>2018</b> , 3, 133-142	4	44
215	Development of In Vivo Imaging Tools for Investigating Astrocyte Activation in Epileptogenesis. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 4463-4472	6.2	3
214	Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. <i>Epilepsia</i> , <b>2018</b> , 59, 79-91	6.4	26
213	n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. <i>Brain</i> , <b>2018</b> , 141, 3130-3143	11.2	41
212	Common data elements and data management: Remedy to cure underpowered preclinical studies. <i>Epilepsy Research</i> , <b>2017</b> , 129, 87-90	3	26
211	Biomarkers of Epileptogenesis: The Focus on Glia and Cognitive Dysfunctions. <i>Neurochemical Research</i> , <b>2017</b> , 42, 2089-2098	4.6	14
210	Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. <i>Brain</i> , <b>2017</b> , 140, 1885-1899	11.2	86
209	Electrocorticographic Dynamics as a Novel Biomarker in Five Models of Epileptogenesis. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 4450-4461	6.6	32
208	Febrile Infection-Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis. <i>Neuropediatrics</i> , <b>2017</b> , 48, 5-18	1.6	56
207	Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. <i>Neurobiology of Disease</i> , <b>2017</b> , 99, 12-23	7.5	114
206	Inhibition of IL-1 $\beta$ Signaling Normalizes NMDA-Dependent Neurotransmission and Reduces Seizure Susceptibility in a Mouse Model of Creutzfeldt-Jakob Disease. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 10278-10289	6.6	22
205	Introduction to the 2nd Meeting on Immunity and Inflammation in Epilepsy (IIE2016). <i>Epilepsia</i> , <b>2017</b> , 58 Suppl 3, 7-10	6.4	4
204	Neuroinflammatory targets and treatments for epilepsy validated in experimental models. <i>Epilepsia</i> , <b>2017</b> , 58 Suppl 3, 27-38	6.4	96
203	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 2118-2132	15.9	60

202	Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 5569-5576	3.3	48
201	Febrile infection-related epilepsy syndrome treated with anakinra. <i>Annals of Neurology</i> , <b>2016</b> , 80, 939-945	9.4	142
200	Advances in the development of biomarkers for epilepsy. <i>Lancet Neurology</i> , <b>2016</b> , 15, 843-856	24.1	200
199	Modulation of neuronal excitability by immune mediators in epilepsy. <i>Current Opinion in Pharmacology</i> , <b>2016</b> , 26, 118-23	5.1	67
198	Current understanding and neurobiology of epileptic encephalopathies. <i>Neurobiology of Disease</i> , <b>2016</b> , 92, 72-89	7.5	60
197	Proteomic profiling of epileptogenesis in a rat model: Focus on inflammation. <i>Brain, Behavior, and Immunity</i> , <b>2016</b> , 53, 138-158	16.6	46
196	Infections, inflammation and epilepsy. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 211-234	14.3	235
195	2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. <i>Epilepsy Currents</i> , <b>2016</b> , 16, 187-193	0.1	6
194	Preventing epileptogenesis: A realistic goal?. <i>Pharmacological Research</i> , <b>2016</b> , 110, 96-100	10.2	29
193	Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy. <i>Neurobiology of Disease</i> , <b>2016</b> , 93, 146-55	7.5	42
192	Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis?. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 583-92	4.1	53
191	GABAA currents are decreased by IL-1 $\beta$ in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis. <i>Neurobiology of Disease</i> , <b>2015</b> , 82, 311-320	7.5	92
190	The immunoproteasome $\beta$ 5 subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy. <i>Brain, Behavior, and Immunity</i> , <b>2015</b> , 49, 188-96	16.6	24
189	Albumin induces excitatory synaptogenesis through astrocytic TGF- $\beta$ /ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction. <i>Neurobiology of Disease</i> , <b>2015</b> , 78, 115-25	7.5	168
188	Neurology--the next 10 years. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 658-64	15	6
187	Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 1081-92	4.3	60
186	Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. <i>Neuropharmacology</i> , <b>2015</b> , 96, 70-82	5.5	354
185	Immunity and Inflammation in Epilepsy. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2015</b> , 6, a022699	5.4	110

184	Inflammation and Immunomodulation in Epilepsy and Its Comorbidities <b>2015</b> , 155-174		3
183	Disulfide-containing high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 21, 1726-40	8.4	114
182	Immune Responses in the CNS in Epilepsy <b>2014</b> , 289-315		1
181	Epilepsy and inflammation in the brain: overview and pathophysiology. <i>Epilepsy Currents</i> , <b>2014</b> , 14, 3-7	1.3	126
180	Does brain inflammation mediate pathological outcomes in epilepsy?. <i>Advances in Experimental Medicine and Biology</i> , <b>2014</b> , 813, 169-83	3.6	45
179	Epilepsy and brain inflammation. <i>Experimental Neurology</i> , <b>2013</b> , 244, 11-21	5.7	366
178	Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. <i>Neurobiology of Disease</i> , <b>2013</b> , 58, 102-14	7.5	121
177	Pharmacological blockade of IL-1/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. <i>Neurobiology of Disease</i> , <b>2013</b> , 59, 183-93	7.5	126
176	Epilepsy biomarkers. <i>Epilepsia</i> , <b>2013</b> , 54 Suppl 4, 61-9	6.4	165
175	The role of inflammation in epileptogenesis. <i>Neuropharmacology</i> , <b>2013</b> , 69, 16-24	5.5	320
174	Glia and epilepsy: excitability and inflammation. <i>Trends in Neurosciences</i> , <b>2013</b> , 36, 174-84	13.3	461
173	The dual role of TNF- $\alpha$ and its receptors in seizures. <i>Experimental Neurology</i> , <b>2013</b> , 247, 267-71	5.7	51
172	Immunity activation in brain cells in epilepsy: mechanistic insights and pathological consequences. <i>Neuropediatrics</i> , <b>2013</b> , 44, 330-5	1.6	10
171	WONOEPI: Workshop summary by the Scientific Organizing Committee. <i>Epilepsia</i> , <b>2012</b> , 53, 1275-6	6.4	
170	Finding a better drug for epilepsy: antiinflammatory targets. <i>Epilepsia</i> , <b>2012</b> , 53, 1113-8	6.4	35
169	Epileptic encephalitis: the role of the innate and adaptive immune system. <i>Brain Pathology</i> , <b>2012</b> , 22, 412-21	6	20
168	Before epilepsy unfolds: finding the epileptogenesis switch. <i>Nature Medicine</i> , <b>2012</b> , 18, 1626-7	50.5	22
167	Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. <i>Epilepsia</i> , <b>2012</b> , 53, 1887-97	6.4	75

166	In vivo imaging of glia activation using 1H-magnetic resonance spectroscopy to detect putative biomarkers of tissue epileptogenicity. <i>Epilepsia</i> , <b>2012</b> , 53, 1907-16	6.4	62
165	Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. <i>Epilepsia</i> , <b>2012</b> , 53 Suppl 6, 37-44	6.4	80
164	Inflammation and epilepsy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 107, 163-75	3	56
163	Brain Autonomous Mechanisms of Seizure-Induced BBB Dysfunction. <i>Epilepsy Currents</i> , <b>2012</b> , 12, 69-71	1.3	1
162	Astrocyte immune responses in epilepsy. <i>Glia</i> , <b>2012</b> , 60, 1258-68	9	134
161	Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. <i>Annals of Neurology</i> , <b>2012</b> , 72, 82-90	9.4	179
160	Glia-Neuron Interactions in Ictogenesis and Epileptogenesis <b>2012</b> , 618-634		16
159	IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. <i>Brain, Behavior, and Immunity</i> , <b>2011</b> , 25, 1281-9	16.6	273
158	Inflammation and prevention of epileptogenesis. <i>Neuroscience Letters</i> , <b>2011</b> , 497, 223-30	3.3	149
157	Brain inflammation as a biomarker in epilepsy. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 607-14	2.3	154
156	The role of inflammation in epilepsy. <i>Nature Reviews Neurology</i> , <b>2011</b> , 7, 31-40	15	1114
155	Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. <i>Journal of Internal Medicine</i> , <b>2011</b> , 270, 319-26	10.8	136
154	The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. <i>Epilepsia</i> , <b>2011</b> , 52, 158-74	6.4	1156
153	The pivotal role of immunity and inflammatory processes in epilepsy is increasingly recognized: introduction. <i>Epilepsia</i> , <b>2011</b> , 52 Suppl 3, 1-4	6.4	30
152	General conclusions. <i>Epilepsia</i> , <b>2011</b> , 52 Suppl 3, 52-3	6.4	1
151	Therapeutic potential of new antiinflammatory drugs. <i>Epilepsia</i> , <b>2011</b> , 52 Suppl 8, 67-9	6.4	35
150	IL-1βs induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence. <i>Neurobiology of Disease</i> , <b>2011</b> , 44, 259-69	7.5	73
149	Acute encephalopathy with inflammation-mediated status epilepticus. <i>Lancet Neurology</i> , <b>2011</b> , 10, 99-108	24.1	154

148	High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. <i>Experimental Neurology</i> , <b>2011</b> , 232, 143-8	5.7	132
147	Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. <i>Neurotherapeutics</i> , <b>2011</b> , 8, 304-15	6.4	218
146	Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. <i>Neurobiology of Disease</i> , <b>2011</b> , 43, 507-15	7.5	80
145	Status epilepticus-induced pathologic plasticity in a rat model of focal cortical dysplasia. <i>Brain</i> , <b>2011</b> , 134, 2828-43	11.2	36
144	Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. <i>Brain</i> , <b>2011</b> , 134, 1015-32	11.2	162
143	Neuronal hyperexcitability and seizures are associated with changes in glial-neuronal interactions in the hippocampus of a mouse model of epilepsy with mental retardation. <i>Journal of Neurochemistry</i> , <b>2010</b> , 115, 1445-54	6	14
142	Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. <i>Gene Therapy</i> , <b>2010</b> , 17, 643-52	4	56
141	Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. <i>Nature Medicine</i> , <b>2010</b> , 16, 413-9	50.5	638
140	Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 7484-94	6.6	198
139	Glia-neuron interactions in epilepsy: Inflammatory mediators. <i>Epilepsia</i> , <b>2010</b> , 51, 55-55	6.4	4
138	Gene therapy of focal-onset epilepsy by adeno-associated virus vector-mediated overexpression of neuropeptide Y. <i>Epilepsia</i> , <b>2010</b> , 51, 96-96	6.4	1
137	Brain Inflammation and Epilepsy <b>2010</b> , 45-59		3
136	ICE/caspase 1 inhibitors and IL-1β receptor antagonists as potential therapeutics in epilepsy. <i>Current Opinion in Investigational Drugs</i> , <b>2010</b> , 11, 43-50		55
135	Basic mechanisms of MCD in animal models. <i>Epileptic Disorders</i> , <b>2009</b> , 11, 206-14	1.9	13
134	Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. <i>Neurobiology of Disease</i> , <b>2009</b> , 34, 121-32	7.5	75
133	Leukocyte-endothelial adhesion mechanisms in epilepsy: cheers and jeers. <i>Epilepsy Currents</i> , <b>2009</b> , 9, 118-21	1.3	10
132	Pilocarpine-induced seizures revisited: what does the model mimic?. <i>Epilepsy Currents</i> , <b>2009</b> , 9, 146-8	1.3	24
131	Basic mechanisms of status epilepticus due to infection and inflammation. <i>Epilepsia</i> , <b>2009</b> , 50 Suppl 12, 56-7	6.4	37



130	Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. <i>Neurotherapeutics</i> , <b>2009</b> , 6, 300-6	6.4	31
129	Molecular and functional interactions between tumor necrosis factor-alpha receptors and the glutamatergic system in the mouse hippocampus: implications for seizure susceptibility. <i>Neuroscience</i> , <b>2009</b> , 161, 293-300	3.9	69
128	Seizure Propensity and Brain Development: A Lesson from Animal Models <b>2009</b> , 77-104		
127	Glia as a source of cytokines: implications for neuronal excitability and survival. <i>Epilepsia</i> , <b>2008</b> , 49 Suppl 2, 24-32	6.4	154
126	Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2X7 receptor-mediated IL-1beta release. <i>Journal of Neurochemistry</i> , <b>2008</b> , 106, 271-80	6	72
125	Epileptogenic role of astrocyte dysfunction. <i>Epilepsy Currents</i> , <b>2008</b> , 8, 46-7	1.3	5
124	Innate immunity and inflammation in temporal lobe epilepsy: new emphasis on the role of complement activation. <i>Epilepsy Currents</i> , <b>2008</b> , 8, 75-7	1.3	22
123	VEGF as a target for neuroprotection. <i>Epilepsy Currents</i> , <b>2008</b> , 8, 135-7	1.3	10
122	Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. <i>Neurobiology of Disease</i> , <b>2008</b> , 29, 142-60	7.5	521
121	Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. <i>Neurobiology of Disease</i> , <b>2008</b> , 31, 327-33	7.5	143
120	Acute induction of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig brain requires enhancement of blood-brain barrier permeability. <i>Neuroscience</i> , <b>2008</b> , 151, 303-12	3.9	66
119	The role of cytokines in the pathophysiology of epilepsy. <i>Brain, Behavior, and Immunity</i> , <b>2008</b> , 22, 797-803	6.6	399
118	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. <i>Brain</i> , <b>2008</b> , 131, 1506-15	11.2	134
117	A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. <i>Brain</i> , <b>2008</b> , 131, 3256-65	11.2	209
116	NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. <i>Hippocampus</i> , <b>2008</b> , 18, 564-74	3.5	47
115	New roles for interleukin-1 Beta in the mechanisms of epilepsy. <i>Epilepsy Currents</i> , <b>2007</b> , 7, 45-50	1.3	166
114	On demand up-regulation of therapeutic genes in the brain: fiction or reality?. <i>Epilepsy Currents</i> , <b>2007</b> , 7, 88-90	1.3	
113	Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1113, 173-7	6.5	95

112	The promise of gene therapy for the treatment of epilepsy. <i>Expert Review of Neurotherapeutics</i> , <b>2007</b> , 7, 1685-92	4.3	19
111	Gene therapy in epilepsy: the focus on NPY. <i>Peptides</i> , <b>2007</b> , 28, 377-83	3.8	49
110	In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. <i>Brain Research</i> , <b>2006</b> , 1086, 201-13	3.7	20
109	Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , <b>2006</b> , 172, 27-37	3.5	97
108	The IL-1beta system in epilepsy-associated malformations of cortical development. <i>Neurobiology of Disease</i> , <b>2006</b> , 24, 128-43	7.5	218
107	Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. <i>Neurobiology of Disease</i> , <b>2006</b> , 24, 429-42	7.5	44
106	Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. <i>Neuroscience</i> , <b>2006</b> , 137, 301-8	3.9	139
105	The toll receptor family: from microbial recognition to seizures. <i>Epilepsy Currents</i> , <b>2006</b> , 6, 11-3	1.3	2
104	Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. <i>Epilepsia</i> , <b>2006</b> , 47, 672-80	6.4	176
103	Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. <i>Epilepsia</i> , <b>2006</b> , 47, 1160-8	6.4	136
102	Gene Therapy for Epilepsy <b>2006</b> , 151-163		
101	Altered expression of GABA(A) and GABA(B) receptor subunit mRNAs in the hippocampus after kindling and electrically induced status epilepticus. <i>Neuroscience</i> , <b>2005</b> , 134, 691-704	3.9	76
100	Neuropeptide Y Y5 receptors inhibit kindling acquisition in rats. <i>Regulatory Peptides</i> , <b>2005</b> , 125, 79-83		16
99	Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 6734-44	6.6	177
98	Tissue plasminogen activator, neuroserpin, and seizures. <i>Epilepsy Currents</i> , <b>2005</b> , 5, 130-2	1.3	2
97	Inflammation and epilepsy. <i>Epilepsy Currents</i> , <b>2005</b> , 5, 1-6	1.3	101
96	VEGF and seizures: cross-talk between endothelial and neuronal environments. <i>Epilepsy Currents</i> , <b>2005</b> , 5, 72-4	1.3	8
95	A pilot study on brain-to-plasma partition of 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. <i>Epilepsia</i> , <b>2005</b> , 46, 1613-9	6.4	74

94	Brain inflammation in epilepsy: experimental and clinical evidence. <i>Epilepsia</i> , <b>2005</b> , 46, 1724-43	6.4	791
93	Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. <i>Epilepsia</i> , <b>2005</b> , 46 Suppl 5, 113-7	6.4	136
92	Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide. <i>Epilepsia</i> , <b>2005</b> , 46 Suppl 5, 125-8	6.4	48
91	The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. <i>European Journal of Neuroscience</i> , <b>2005</b> , 22, 1417-30	3.5	108
90	Interleukin-1beta contributes to the generation of experimental febrile seizures. <i>Annals of Neurology</i> , <b>2005</b> , 57, 152-5	9.4	315
89	Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. <i>Annals of Neurology</i> , <b>2005</b> , 57, 804-12	9.4	150
88	Neuropeptide Y and Its Receptors in Kindling Epileptogenesis <b>2005</b> , 249-261		
87	Antiepileptic effects of botulinum neurotoxin E. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 1943-51	6.6	77
86	Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. <i>Journal of Neuroscience</i> , <b>2004</b> , 24, 3051-9	6.6	209
85	Functional role of proinflammatory and anti-inflammatory cytokines in seizures. <i>Advances in Experimental Medicine and Biology</i> , <b>2004</b> , 548, 123-33	3.6	39
84	Brain Inflammation and Seizures. <i>Epilepsy Currents</i> , <b>2004</b> , 4, 73-75	1.3	6
83	Gene therapy in epilepsy. <i>Epilepsy Currents</i> , <b>2004</b> , 4, 87-90	1.3	18
82	Neuropeptide Y and Y1 receptors in kindling epileptogenesis. <i>Epilepsy Currents</i> , <b>2004</b> , 4, 100-2	1.3	
81	Plasticity of somatostatin and somatostatin sst2A receptors in the rat dentate gyrus during kindling epileptogenesis. <i>European Journal of Neuroscience</i> , <b>2004</b> , 19, 2531-8	3.5	24
80	Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?. <i>Neuropeptides</i> , <b>2004</b> , 38, 245-52	3.3	135
79	Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. <i>BMC Medicine</i> , <b>2004</b> , 2, 37	11.4	106
78	Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. <i>Epilepsy Research</i> , <b>2004</b> , 60, 203-13	3	50
77	Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. <i>Development (Cambridge)</i> , <b>2004</b> , 131, 3805-19	6.6	501

76	Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 8692-700	6.6	679
75	Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. <i>European Journal of Neuroscience</i> , <b>2003</b> , 18, 143-8	3.5	158
74	Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. <i>European Journal of Neuroscience</i> , <b>2003</b> , 18, 2087-92	3.5	102
73	Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. <i>Neurobiology of Disease</i> , <b>2003</b> , 14, 494-503	7.5	201
72	Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 5833-9	6.6	218
71	Expression of glutamate receptor subtypes in the spinal cord of control and mnd mice, a model of motor neuron disorder. <i>Journal of Neuroscience Research</i> , <b>2002</b> , 70, 553-60	4.4	23
70	Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis. <i>Epilepsia</i> , <b>2002</b> , 43 Suppl 5, 30-5	6.4	300
69	Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. <i>European Journal of Neuroscience</i> , <b>2002</b> , 16, 843-9	3.5	68
68	Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. <i>Neuroscience</i> , <b>2002</b> , 110, 237-43	3.9	87
67	Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. <i>Neuroscience</i> , <b>2001</b> , 105, 43-53	3.9	75
66	Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. <i>European Journal of Neuroscience</i> , <b>2000</b> , 12, 2623-33	3.5	378
65	Modulatory role of neuropeptides in seizures induced in rats by stimulation of glutamate receptors. <i>Journal of Nutrition</i> , <b>2000</b> , 130, 1046S-8S	4.1	31
64	Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 11534-9	11.5	368
63	Autoradiographic reevaluation of the binding properties of 125I-[Leu31,Pro34]peptide YY and 125I-peptide YY3-36 to neuropeptide Y receptor subtypes in rat forebrain. <i>Journal of Neurochemistry</i> , <b>1999</b> , 72, 1663-70	6	11
62	Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. <i>Journal of Neuroscience</i> , <b>1999</b> , 19, 5054-65	6.6	484
61	Biochemical and pharmacological evidence of a functional role of AMPA receptors in motor neuron dysfunction in mnd mice. <i>European Journal of Neuroscience</i> , <b>1999</b> , 11, 1705-10	3.5	14
60	Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. <i>European Journal of Neuroscience</i> , <b>1999</b> , 11, 3767-76	3.5	113
59	Brain-derived neurotrophic factor immunoreactivity in the limbic system of rats after acute seizures and during spontaneous convulsions: temporal evolution of changes as compared to neuropeptide Y. <i>Neuroscience</i> , <b>1999</b> , 90, 1445-61	3.9	92

58	Neuropeptide Y: emerging evidence for a functional role in seizure modulation. <i>Trends in Neurosciences</i> , <b>1999</b> , 22, 25-30	13.3	411
57	Anticonvulsant properties of BIBP3226, a non-peptide selective antagonist at neuropeptide Y Y1 receptors. <i>European Journal of Neuroscience</i> , <b>1998</b> , 10, 757-9	3.5	74
56	Time- and region-specific variations in somatostatin release following amygdala kindling in the rat. <i>Journal of Neurochemistry</i> , <b>1998</b> , 70, 252-9	6	7
55	Lasting increase in serotonin 5-HT1A but not 5-HT4 receptor subtypes in the kindled rat dentate gyrus: dissociation from local presynaptic effects. <i>Journal of Neurochemistry</i> , <b>1998</b> , 70, 850-7	6	10
54	Distinct changes in peptide YY binding to, and mRNA levels of, Y1 and Y2 receptors in the rat hippocampus associated with kindling epileptogenesis. <i>Journal of Neurochemistry</i> , <b>1998</b> , 70, 1615-22	6	66
53	Somatostatin-and Neuropeptide Y-Mediated Neurotransmission in Kindling Epileptogenesis. <i>Advances in Behavioral Biology</i> , <b>1998</b> , 313-325		2
52	Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death: role of cyclic GMP. <i>Journal of Neurochemistry</i> , <b>1997</b> , 68, 319-27	6	45
51	Agonists and Antagonists at Neuropeptide (i.e., Somatostatin and Neuropeptide Y) Receptors in the CNS [1,2]. <i>Expert Opinion on Therapeutic Targets</i> , <b>1997</b> , 1, 101-103		
50	Autoradiographic analysis of neuropeptide Y receptor binding sites in the rat hippocampus after kainic acid-induced limbic seizures. <i>Neuroscience</i> , <b>1996</b> , 70, 47-55	3.9	67
49	Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. <i>British Journal of Pharmacology</i> , <b>1996</b> , 119, 813-8	8.6	41
48	Functional activation of somatostatin- and neuropeptide Y-containing neurons in the entorhinal cortex of chronically epileptic rats. <i>Neuroscience</i> , <b>1996</b> , 75, 551-7	3.9	17
47	Status of somatostatin receptor messenger RNAs and binding sites in rat brain during kindling epileptogenesis. <i>Neuroscience</i> , <b>1996</b> , 75, 857-68	3.9	18
46	Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. <i>Brain Research Reviews</i> , <b>1996</b> , 22, 27-50		121
45	Cellular localization of neuropeptide-Y receptors in the rat hippocampus: long-term effects of limbic seizures. <i>NeuroReport</i> , <b>1996</b> , 7, 1475-80	1.7	16
44	Functional changes in somatostatin and neuropeptide Y containing neurons in the rat hippocampus in chronic models of limbic seizures. <i>Epilepsy Research</i> , <b>1996</b> , 26, 267-79	3	58
43	Regional production of nitric oxide after a peripheral or central low dose of LPS in mice. <i>NeuroImmunoModulation</i> , <b>1996</b> , 3, 364-70	2.5	6
42	Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis <b>1996</b> , 22, 27-27		7
41	Functional activation of somatostatin and neuropeptide Y containing neurons in experimental models of limbic seizures. <i>Epilepsy Research Supplement</i> , <b>1996</b> , 12, 187-95		3

40	Alternative splicing at the C-terminal but not at the N-terminal domain of the NMDA receptor NR1 is altered in the kindled hippocampus. <i>European Journal of Neuroscience</i> , <b>1995</b> , 7, 2513-7	3.5	31
39	Trans-synaptic modulation of striatal ACh release in vivo by the parafascicular thalamic nucleus. <i>European Journal of Neuroscience</i> , <b>1995</b> , 7, 1117-20	3.5	31
38	Extracellular glutamate levels in the hypothalamus and hippocampus of rats after acute or chronic oral intake of monosodium glutamate. <i>Neuroscience Letters</i> , <b>1995</b> , 193, 45-8	3.3	22
37	Electrical kindling is associated with a lasting increase in the extracellular levels of kynurenic acid in the rat hippocampus. <i>Neuroscience Letters</i> , <b>1995</b> , 198, 91-4	3.3	15
36	Functional effects of D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH <sub>2</sub> and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. <i>Neuroscience</i> , <b>1995</b> , 65, 1087-97	3.9	60
35	Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. <i>Neuroscience</i> , <b>1995</b> , 69, 831-45	3.9	146
34	Enhanced neuropeptide Y release in the hippocampus is associated with chronic seizure susceptibility in kainic acid treated rats. <i>Brain Research</i> , <b>1994</b> , 660, 138-43	3.7	63
33	Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551. <i>European Journal of Pharmacology</i> , <b>1994</b> , 271, 93-101	5.3	4
32	Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 8047-51	11.5	75
31	Changes in the ADP-ribosylation status of some hippocampal proteins are linked to kindling progression. <i>NeuroReport</i> , <b>1994</b> , 5, 1217-20	1.7	7
30	Electrical kindling of the hippocampus is associated with functional activation of neuropeptide Y-containing neurons. <i>European Journal of Neuroscience</i> , <b>1993</b> , 5, 1534-8	3.5	65
29	Increased expression of GAP-43, somatostatin and neuropeptide Y mRNA in the hippocampus during development of hippocampal kindling in rats. <i>European Journal of Neuroscience</i> , <b>1993</b> , 5, 1312-20	3.5	60
28	Extracellular somatostatin measured by microdialysis in the hippocampus of freely moving rats: evidence for neuronal release. <i>Journal of Neurochemistry</i> , <b>1993</b> , 60, 671-7	6	30
27	Anti-somatostatin antibody enhances the rate of hippocampal kindling in rats. <i>Brain Research</i> , <b>1993</b> , 602, 148-52	3.7	45
26	Somatostatin release is enhanced in the hippocampus of partially and fully kindled rats. <i>Neuroscience</i> , <b>1992</b> , 51, 41-6	3.9	43
25	Chronic infusion of quinolinic acid in rat striatum: effects on discrete neuronal populations. <i>Journal of the Neurological Sciences</i> , <b>1992</b> , 108, 129-36	3.2	21
24	Epileptogenic activity of two peptides derived from diazepam binding inhibitor after intrahippocampal injection in rats. <i>Epilepsia</i> , <b>1991</b> , 32, 597-603	6.4	13
23	Neurodegenerative Effects Induced by Chronic Infusion of Quinolinic Acid in Rat Striatum and Hippocampus. <i>European Journal of Neuroscience</i> , <b>1991</b> , 3, 40-46	3.5	14

22	Increased preproneuropeptide Y mRNA in the rat hippocampus during the development of hippocampal kindling: comparison with the expression of preprosomatostatin mRNA. <i>Neuroscience Letters</i> , <b>1991</b> , 132, 175-8	3.3	35
21	Functional and histological consequences of quinolinic and kainic acid-induced seizures on hippocampal somatostatin neurons. <i>Neuroscience</i> , <b>1991</b> , 41, 127-35	3.9	38
20	Changes in pre- and postsynaptic components of noradrenergic transmission in hippocampal kindling in rats. <i>Brain Research</i> , <b>1991</b> , 557, 210-6	3.7	5
19	A peptidase-resistant cyclic octapeptide analogue of somatostatin (SMS 201-995) modulates seizures induced by quinolinic and kainic acids differently in the rat hippocampus. <i>Neuropharmacology</i> , <b>1991</b> , 30, 345-52	5.5	62
18	Kynurenic acid synthesis by human glioma. <i>Journal of the Neurological Sciences</i> , <b>1990</b> , 99, 51-7	3.2	13
17	Autoradiographical analysis of excitatory amino acid binding sites in rat hippocampus during the development of hippocampal kindling. <i>Brain Research</i> , <b>1990</b> , 526, 113-21	3.7	25
16	Effect of aspartame on seizures in various models of experimental epilepsy. <i>Toxicology and Applied Pharmacology</i> , <b>1988</b> , 96, 485-93	4.6	14
15	Quinolinic acid-induced seizures, but not nerve cell death, are associated with extracellular Ca <sup>2+</sup> decrease assessed in the hippocampus by brain dialysis. <i>Brain Research</i> , <b>1988</b> , 454, 289-97	3.7	17
14	Effect of various calcium channel blockers on three different models of limbic seizures in rats. <i>Neuropharmacology</i> , <b>1988</b> , 27, 451-8	5.5	47
13	Role of the N-methyl-D-aspartate-type receptors in the development and maintenance of hippocampal kindling in rats. <i>Neuroscience Letters</i> , <b>1988</b> , 87, 63-8	3.3	115
12	Norepinephrine modulates seizures induced by quinolinic acid in rats: selective and distinct roles of alpha-adrenoceptor subtypes. <i>European Journal of Pharmacology</i> , <b>1987</b> , 138, 309-18	5.3	22
11	ATP as a marker of excitotoxin-induced nerve cell death in vivo. <i>Journal of Neural Transmission</i> , <b>1987</b> , 70, 349-56	4.3	6
10	[3H]norepinephrine release from hippocampal slices is an in vitro biochemical tool for investigating the pharmacological properties of excitatory amino acid receptors. <i>Journal of Neurochemistry</i> , <b>1987</b> , 49, 1438-42	6	68
9	Determination of endogenous acetylcholine release in freely moving rats by transstriatal dialysis coupled to a radioenzymatic assay: effect of drugs. <i>Journal of Neurochemistry</i> , <b>1987</b> , 48, 1459-65	6	105
8	In vivo and in vitro studies on the regulation of cholinergic neurotransmission in striatum, hippocampus and cortex of aged rats. <i>Brain Research</i> , <b>1986</b> , 374, 212-8	3.7	55
7	Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>1986</b> , 239, 256-63	4.7	29
6	In vivo brain dialysis of amino acids and simultaneous EEG measurements following intrahippocampal quinolinic acid injection: evidence for a dissociation between neurochemical changes and seizures. <i>Journal of Neurochemistry</i> , <b>1985</b> , 45, 335-44	6	97
5	A noradrenergic component of quinolinic acid-induced seizures. <i>Experimental Neurology</i> , <b>1985</b> , 90, 254-85.7		13

4	Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. <i>Neuroscience Letters</i> , <b>1984</b> , 48, 273-8	3-3	34 <sup>1</sup>
3	Mode of action of gamma-butyrolactone on the central cholinergic system. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1983</b> , 322, 42-8	3-4	25
2	White matter abnormalities across different epilepsy syndromes in adults: an ENIGMA Epilepsy study		1
1	A systems-level analysis highlights microglial activation as a modifying factor in common forms of human epilepsy		6